By Will Feuer

Becton Dickinson's sales and adjusted earnings outlook for fiscal 2024 are below Wall Street analysts' expectations, dragged down by currency fluctuations and softening demand for Covid-19 testing.

The medical-device maker is targeting fiscal-year revenue of $20.1 billion to $20.3 billion, below the $20.35 billion that analysts surveyed by FactSet expected.

The company said it is targeting organic sales growth of 5.25% to 6.25%, including a more than 25-basis-points hit from the expected decline in Covid-19-only testing demand. Foreign-exchange rates are expected to reduce sales growth by about 75 basis points.

Becton Dickinson is targeting adjusted earnings for the year of $12.70 a share to $13.00 a share, below the $13.48 a share that analysts expected, according to FactSet.

Write to Will Feuer at Will.Feuer@wsj.com

(END) Dow Jones Newswires

November 09, 2023 07:08 ET (12:08 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Becton Dickinson Charts.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Becton Dickinson Charts.